Medica 2026
Nov 16-19, 2026 - Düsseldorf, Germany

Ultrapure Lipopolysaccharides (LPS) (Escherichia coli 0111:B4, TLR4 tested, vaccine adjuvant)

Cat.No.
DADF-067
Product Name
Ultrapure Lipopolysaccharides (LPS) (Escherichia coli 0111:B4, TLR4 tested, vaccine adjuvant)
Subclassification
Vaccine grade-PRR Ligands-based adjuvant
Classification
Adjuvant
Storage
Shipped at room temperature, for powder in cold paks and it should be stored at -20°C or below. DO NOT FREEZE. Stable for 6 months.
Description
Lipopolysaccharides (LPSs) are characteristic components of the cell wall of Gram-negative bacteria. LPS and its lipid A moiety
stimulate cells of the innate immune system by the Toll-like receptor 4 (TLR4), a member of the Toll-like receptor protein family, which recognizes common pathogen-associated molecular-patterns (PAMPs). This product is phenol extracted from E. coli serotype O111:B4. This LPS serotype has been used to stimulate B-cells and induce NOS in human hepatocytes. Bacteria with common serotypes have surface antigens (group O, group H, or LPS) which generate the same antibody response.
Format
lyophilized
Online Inquiry
Inquiry Basket
loading Loading ......

Inquiry

Inquiry